Skip to main content

Table 2 Comparison of liver function, renal function, blood routine and performance status after treatment between the two groups

From: Efficacy and safety analysis of TACE + sunitinib vs. sunitinib in the treatment of unresectable advanced renal cell carcinoma: a retrospective study

 

Group

Chi-Square Tests(p-value)

t-test(p-value)

TACE + Sunitinib group(N = 47)

Sunitinib group(N = 51)

Pearson Chi-Square

Fisher’s Exact Test

 

Post-Treatment ECOG

0

Count(%)

11(23.4%)

11(21.6%)

0.570

  

1

Count(%)

24(51.1%)

22(43.1%)

2

Count(%)

12(25.5%)

18(35.3%)

Post-treatment liver function

Child A

Count(%)

32(68.1%)

33(64.7%)

 

0.831

 

Child B

Count(%)

15(31.9%)

18(35.3%)

Post-treatment bilirubin(µmol/L)

Mean ± SD

16.1 ± 4.8

15.0 ± 5.3

  

0.306

Post-treatment Albumin(g/L)

Mean ± SD

35.76 ± 5.41

33.37 ± 3.05

  

0.008

Post-treatment BUN(mmol/L)

Mean ± SD

7.71 ± 0.89

7.54 ± 0.98

  

0.347

Post-Treatment Cr(µmol/L)

Mean ± SD

110.3 ± 20.8

105.0 ± 25.6

  

0.269

Post-Treatment GFR(ml/min)

Mean ± SD

95.78 ± 12.97

99.34 ± 12.46

  

0.168

Post-Treatment WBC(G/L)

Mean ± SD

6.92 ± 0.72

3.52 ± 0.73

  

< 0.001

Post-Treatment RBC(T/L)

Mean ± SD

3.64 ± 0.66

3.37 ± 0.74

  

0.062

Post-Treatment PLT(G/L)

Mean ± SD

95.40 ± 18.03

87.90 ± 23.32

  

0.080